Below is an institutional research note written by Hedgeye Healthcare analyst Thomas Tobin and Andrew Freedman. After falling -21% since Mednax was named to the Healthcare team's short list, Tobin and Freedman still see around -25% downside for shares.
*If you're an institutional investor email sales@hedgeye.com to read Hedgeye's Healthcare research notes.
